Literature DB >> 20969464

Noncirrhotic portal hypertension in HIV-infected patients: a case control evaluation and review of the literature.

Miriam Cesari1, Monica Schiavini, Giulia Marchetti, Ilaria Caramma, Massimiliano Ortu, Fabio Franzetti, Massimo Galli, Spinello Antinori, Laura Milazzo.   

Abstract

Idiopathic noncirrhotic portal hypertension (NCPH) is an infrequent but possibly underestimated cryptogenetic liver disease recently described in small series of HIV-infected patients. The exposure to antiretroviral drugs, a direct role of HIV itself, microbial translocation from the gut, or a thrombophilic propensity have been suggested as possible pathogenic mechanisms. In this case control study, we describe 11 HIV-infected patients with idiopathic NCPH and compare the activity of protein C and S, and soluble CD14 levels (a surrogate marker of the translocation of intestinal bacterial products) with 10 age- and gender-matched HIV-infected controls with no liver disease. The clinical presentation of the 11 patients with NCPH was characterised by acute variceal bleeding (2/11), ascites (2/11), portal thrombosis (2/11), and ultrasonographic and endoscopic signs of portal hypertension (11/11), with slightly high alanine transaminase (ALT) and γglutamyl transpeptidase (γ-GT) levels. The FibroScan median liver stiffness was 8.1 kPa, which is inconsistent with significant fibrosis, and nodular regenerative hyperplasia was diagnosed in the 5 patients who underwent liver biopsy. The NCPH patients showed no impairment of hepatic synthesis, but had lower serum albumin levels and a higher international normalized ratio (INR) than the controls (p = 0.01), and lower protein C and S activity, although within the normal range (p = 0.02 and 0.3, respectively). No significant difference in soluble CD14 was seen between the two groups. In conclusion, the etiology of NCHP is not still established, but in order to prevent the dramatic complications of portal hypertension, all HIV-infected patients with unexplained liver enzyme abnormalities or thrombocytopenia should be considered for further investigations by means of thrombophilic screening, Doppler ultrasound evaluation, and in the presence of portal hypertension, endoscopy and liver biopsy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20969464     DOI: 10.1089/apc.2010.0160

Source DB:  PubMed          Journal:  AIDS Patient Care STDS        ISSN: 1087-2914            Impact factor:   5.078


  6 in total

1.  Didanosine Exposure and Noncirrhotic Portal Hypertension in a HIV Clinic in North America: a Follow-up Study.

Authors:  Edward R Cachay; Michael R Peterson; Miguel Goicoechea; William C Mathews
Journal:  Br J Med Med Res       Date:  2011

Review 2.  Clinical applications, limitations and future role of transient elastography in the management of liver disease.

Authors:  Pik Eu Chang; George Boon-Bee Goh; Jing Hieng Ngu; Hiang Keat Tan; Chee Kiat Tan
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

3.  Human immunodeficiency virus infection and the liver.

Authors:  Megan Crane; David Iser; Sharon R Lewin
Journal:  World J Hepatol       Date:  2012-03-27

4.  [Noncirrhotic portal hypertension in a human immunodeficiency virus (HIV) infected adolescent].

Authors:  Aída de Fátima Thomé Barbosa Gouvêa; Daisy Maria Machado; Suênia Cordeiro de Vasconcelos Beltrão; Fabiana Bononi do Carmo; Regina Helena Guedes Motta Mattar; Regina Célia de Menezes Succi
Journal:  Rev Paul Pediatr       Date:  2015-03-27

Review 5.  Human immunodeficiency virus and nodular regenerative hyperplasia of liver: A systematic review.

Authors:  Archita Sood; Mariana Castrejón; Sammy Saab
Journal:  World J Hepatol       Date:  2014-01-27

Review 6.  Microbial translocation in HIV infection: causes, consequences and treatment opportunities.

Authors:  Netanya G Sandler; Daniel C Douek
Journal:  Nat Rev Microbiol       Date:  2012-08-13       Impact factor: 60.633

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.